论文部分内容阅读
心力衰竭(HF)是多种心血管疾病的最终临床转归,其中心脏病理性重构是HF重要的病理生理基础。目前尚缺乏针对心脏病理性重构的特异性治疗手段,因此目前对于HF的治疗尚无法从本质上改变其生物学特性。组蛋白去乙酰化酶(HDACs)作为一种重要的表观遗传调控机制,已经被证实参与调控多条心脏病理性进程通路。同时多种针对特定HDACs的靶向干预药物已经面试,这为HF的治疗提供了全新的视角和思路。本文将对HDACs在心脏病理性重构中的意义及潜在靶向干预靶点进行综述。
Heart failure (HF) is the definitive clinical outcome of many cardiovascular diseases, where cardio-pathological remodeling is an important pathophysiologic basis for HF. At present, there is no specific treatment for cardiac pathological remodeling, so the current treatment of HF can not fundamentally change its biological characteristics. As an important epigenetic regulatory mechanism, histone deacetylases (HDACs) have been shown to be involved in the regulation of multiple cardiac pathways. At the same time, a variety of targeted interventional drugs targeting specific HDACs have been interviewed, which provides a completely new perspective and thought for the treatment of HF. This article reviews the significance of HDACs in cardiac pathologic remodeling as well as the potential targets of targeted interventions.